The Deal That Wasn’t: Inside Biotech’s Ghost Round Epidemic
In the spring of 2025, biotech startups find themselves navigating an increasingly treacherous fundraising landscape. While headlines boast of massive
The Long and Short of Family Office Investing
Family offices are often portrayed as paragons of “patient capital,” stewards of dynastic wealth with investment horizons stretching across generations.
Royalty Strategies in Biotech: Evolution, Key Players, and the Capital for Cures Approach
Biotech companies often face a critical funding gap: bringing a new therapy from lab to market is exceedingly expensive, yet
The Middlemen’s Middlemen: How Fund-of-Funds Make Money by Investing in People Who Invest in Other People
Venture capital, like most human activities involving large sums of money and delayed gratification, has developed a hierarchy. At the
Vintages and Valuations: Why Timing Is Everything in Biotech VC
In venture capital, your returns depend less on genius and more on calendar luck. Especially in biotech.
Venture capitalists like
The Last Cheques in Europe
Biotech, we were told, had entered its age of austerity. The days of bloated valuations and preclinical moonshots were over.
The Venture Winter: Rethinking Biotech's Funding Future Amidst Scarcity
The pronouncement that "It’s Never Been Harder to Make It in Venture Capital," as captured by Bloomberg,
Rethinking Biotech Financing
At the recent Capital for Cures gathering in Milan, a curated group of biotech innovators, investors, and family office leaders
The QALY: Health Economics’ Favorite Yardstick—or a Misguided Ruler?
If you’ve ever wondered how governments decide which new drugs to fund and which to reject, chances are the
How Europe Can Compete in the Global Biotech Race: Lessons from the Capital for Cures Event Series
If biotech were a footrace, Europe would be the competitor with flawless running shoes, world-class muscle tone—and one leg
